Assessing a heart transplant patient's risk for organ rejection just got easier. The FDA approved a new test called AlloMap, which measures genetic information in a patient's white blood cells. The test then assigns a score indicating whether the body appears to be rejecting the new organ. White blood cells are involved in the immune system and help the body fight infection. The test costs about $3,000.
The previous method to assess rejection required a biopsy of heart tissue.